Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403

Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Daisuke Minami, Toshi Murakami, Toshihide Yokoyama, Daijiro Harada, Shoichi Kuyama, Hirohisa Ichikawa, Koji Inoue, Daizo Kishino, Masaaki Inoue, Nagio Takigawa, Takuo Shibayama, Shingo Harita, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy. However, acquired resistance often occurs within 12 months. One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. The aim of the present study is to investigate the efficacy and safety of EGFR-TKI readministration with afatinib in patients with advanced NSCLC harboring activating EGFR mutations without T790M. The primary endpoint is progression-free survival. The secondary endpoints include the objective response rate, disease control rate, overall survival, toxicity, and quality of life. A total of 12 patients will be enrolled in this trial.

Original languageEnglish
Pages (from-to)241-244
Number of pages4
JournalClinical Lung Cancer
Volume18
Issue number2
DOIs
Publication statusPublished - Mar 1 2017

Keywords

  • Epidermal growth factor receptor
  • Non–small-cell lung cancer
  • Readministration
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403'. Together they form a unique fingerprint.

Cite this